Literature DB >> 3829343

Idiopathic ventricular fibrillation: inducibility and beneficial effects of class I antiarrhythmic agents.

B Belhassen, I Shapira, D Shoshani, A Paredes, H Miller, S Laniado.   

Abstract

Ventricular fibrillation in patients without recognizable heart disease is uncommon and electrophysiologic data on such patients is limited. Over a 7 year period, five patients (three men and two women, ranging in age from 24 to 52 years) without demonstrable heart disease underwent electrophysiologic studies with pharmacologic drug testing because of single (four patients) or multiple (one patient) documented episodes of ventricular fibrillation. The arrhythmic event was unrelated to myocardial ischemia or infarction, metabolic or electrolyte disturbances, drug toxicity, preexcitation, or prolonged QT syndromes. In all three patients receiving no antiarrhythmic drugs and in two pretreated with amiodarone, a rapid poorly tolerated ventricular tachyarrhythmia requiring cardioversion was induced by programmed ventricular stimulation with up to two extrastimuli. In all instances, addition of either oral quinidine or oral disopyramide prevented the induction of sustained ventricular arrhythmias. All five patients were placed on antiarrhythmic drug regimens found effective during electrophysiologic studies and remained asymptomatic during follow-up periods ranging from 12 to 93 (mean 52) months. We conclude that in the patients with idiopathic ventricular fibrillation in our study: programmed ventricular stimulation reliably replicated the spontaneous arrhythmia, class I antiarrhythmic agents effectively prevented induction of the arrhythmia in the laboratory, and in contrast to the severity of the presenting arrhythmia, a benign clinical course was observed during long-term therapy with class I antiarrhythmic agents.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3829343     DOI: 10.1161/01.cir.75.4.809

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  15 in total

Review 1.  J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge.

Authors:  Charles Antzelevitch; Gan-Xin Yan; Michael J Ackerman; Martin Borggrefe; Domenico Corrado; Jihong Guo; Ihor Gussak; Can Hasdemir; Minoru Horie; Heikki Huikuri; Changsheng Ma; Hiroshi Morita; Gi-Byoung Nam; Frederic Sacher; Wataru Shimizu; Sami Viskin; Arthur A M Wilde
Journal:  Europace       Date:  2017-04-01       Impact factor: 5.214

Review 2.  J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge.

Authors:  Charles Antzelevitch; Gan-Xin Yan; Michael J Ackerman; Martin Borggrefe; Domenico Corrado; Jihong Guo; Ihor Gussak; Can Hasdemir; Minoru Horie; Heikki Huikuri; Changsheng Ma; Hiroshi Morita; Gi-Byoung Nam; Frederic Sacher; Wataru Shimizu; Sami Viskin; Arthur A M Wilde
Journal:  Heart Rhythm       Date:  2016-07-13       Impact factor: 6.343

3.  Sudden cardiac death in the young: how can disease recognition and prevention in family members be improved?

Authors:  Rainer Schimpf; Katrin Yen; Martin Borggrefe
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2012-09

4.  Isoprenaline and quinidine to calm Brugada VF storm.

Authors:  Guy Furniss
Journal:  BMJ Case Rep       Date:  2012-08-13

Review 5.  J-wave syndromes: Brugada and early repolarization syndromes.

Authors:  Charles Antzelevitch; Gan-Xin Yan
Journal:  Heart Rhythm       Date:  2015-04-11       Impact factor: 6.343

Review 6.  J wave syndromes as a cause of malignant cardiac arrhythmias.

Authors:  José M Di Diego; Charles Antzelevitch
Journal:  Pacing Clin Electrophysiol       Date:  2018-06-30       Impact factor: 1.976

7.  Prevalence of the Brugada sign in idiopathic ventricular fibrillation and healthy controls.

Authors:  S Viskin; R Fish; M Eldar; D Zeltser; M D Lesh; A Glick; B Belhassen
Journal:  Heart       Date:  2000-07       Impact factor: 5.994

8.  Ventricular fibrillation associated with complete right bundle branch block.

Authors:  Yoshiyasu Aizawa; Seiji Takatsuki; Takehiro Kimura; Nobuhiro Nishiyama; Kotaro Fukumoto; Yoko Tanimoto; Kojiro Tanimoto; Shunichiro Miyoshi; Makoto Suzuki; Yasuhiro Yokoyama; Masaomi Chinushi; Ichiro Watanabe; Satoshi Ogawa; Yoshifusa Aizawa; Charles Antzelevitch; Keiichi Fukuda
Journal:  Heart Rhythm       Date:  2013-03-14       Impact factor: 6.343

9.  Cost-effectiveness of implantable cardioverter-defibrillators in Brugada syndrome treatment.

Authors:  Kai Wang; Kazunobu Yamauchi; Ping Li; Hiroki Kato; Makoto Kobayashi; Ken Kato; Yoshiyuki Shimizu
Journal:  J Med Syst       Date:  2008-02       Impact factor: 4.460

Review 10.  Pharmacological Therapy in Brugada Syndrome.

Authors:  Oholi Tovia Brodie; Yoav Michowitz; Bernard Belhassen
Journal:  Arrhythm Electrophysiol Rev       Date:  2018-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.